Ignite Creation Date:
2025-12-25 @ 12:43 AM
Ignite Modification Date:
2026-01-07 @ 2:22 PM
Study NCT ID:
NCT03163667
Status:
COMPLETED
Last Update Posted:
2022-09-15
First Post:
2017-05-21
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
CB-839 With Everolimus vs. Placebo With Everolimus in Participants With Renal Cell Carcinoma (RCC)
Sponsor:
Calithera Biosciences, Inc
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2017-09-06
Start Date Type:
ACTUAL
Primary Completion Date:
2019-04-26
Primary Completion Date Type:
ACTUAL
Completion Date:
2020-06-01
Completion Date Type:
ACTUAL
First Submit Date:
2017-05-21
First Submit QC Date:
None
Study First Post Date:
2017-05-23
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2022-07-18
Results First Submit QC Date:
None
Results First Post Date:
2022-09-15
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
2022-09-15
Disp First Post Date Type:
ACTUAL
Last Update Submit Date:
2022-08-19
Last Update Post Date:
2022-09-15
Last Update Post Date Type:
ACTUAL